ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

ngµç×ÓÓÎÏ·ÍŶÓ̽Ìָΰ©¶àѧ¿ÆÁªºÏÖÎÁÆÐ·½°¸

¸å¼þȪԴ£ºÁ¥ÊôµÚÈýÒ½Ôº ±à¼­£ºÌ¸Ï£¡£¡¢¡¢Íõ¶¬Ã· ÉóºË£ºËïÒ«±ó ÔĶÁÁ¿£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±Ò¶ÁÖÉ­£©¿ËÈÕ£¬£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÈýÒ½ÔºÑîÑï½ÌÊÚÍŶÓÔÚ¹ú¼Ê×ÅÃûÆÚ¿¯Nature communications½ÒÏþÌâΪ¡°Low-dose Radiotherapy Combined with Dual PD-L1 and VEGFA Blockade Elicits Antitumor Response in Hepatocellular Carcinoma Mediated by Activated Intratumoral CD8+ exhausted-like T cells¡± µÄÑо¿Ð§¹û¡£¡£¡£

ngµç×ÓÓÎÏ·Á¥ÊôµÚÈýҽԺΪÂÛÎĵÚÒ»ºÍ×îºóͨѶµ¥Î»£¬£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÈýÒ½ÔºÑîÑï½ÌÊÚ¡¢¡¢Ò¶ÁÖÉ­Ö÷ÖÎҽʦ£¬£¬£¬Ë®Ê¦¾üÒ½´óѧµÚÈýÁ¥ÊôÒ½Ôº£¨¶«·½¸Îµ¨Íâ¿ÆÒ½Ôº£¬£¬£¬¶«·½¸Îµ¨Íâ¿ÆÑо¿Ëù£©³ÌÊ÷Ⱥ½ÌÊÚ£¬£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÈýÒ½ÔºÀ½ÌÊÚΪÅäºÏͨѶ×÷Õß¡£¡£¡£ngµç×ÓÓÎÏ·Á¥ÊôµÚÈýÒ½ÔºÀî˼ç÷²©Ê¿¡¢¡¢ÀîÀ¤²©Ê¿ºóºÍ¶«·½¸Îµ¨Íâ¿ÆÒ½ÔºÍõ¿µ½ÌÊÚΪ¸ÃÑо¿ÂÛÎÄÅäºÏµÚÒ»×÷Õß¡£¡£¡£

½üÄêÀ´£¬£¬£¬°¢ÌæÀûÖéµ¥¿¹£¨anti-PD-L1£©ÁªºÏ±´·¥Öéµ¥¿¹£¨anti-VEGFA£©£¨¡°T+A¡±·½°¸£©ÔÚ²»¿ÉÇгý¸Î°©µÄÖÎÁÆÖÐÏÔʾ³öÓÅÒìµÄÁÆÐ§¡£¡£¡£IIIÆÚÁÙ´²ÊÔÑéIMbrave150ÏÔʾ£¬£¬£¬T+AÖÎÁÆ×é±ÈË÷À­·ÇÄáÖÎÁÆ×éչʾ¸ü³¤µÄ×ÜÉúÑÄÆÚºÍÎÞÏ£ÍûÉúÑÄÆÚ£¬£¬£¬ÊÇÊ׸ö¸Îϸ°û°©Ò»ÏßÃâÒßÖÎÁÆ·½°¸¡£¡£¡£ËäÈ»T+AÖÎÁƽÏË÷À­·ÇÄáÖÎÁÆ»ñµÃÁ˸üºÃµÄÉúÑÄϳ¡£¬£¬£¬µ«ÈÔÖ»ÓÐ27.3%µÄHCC»¼Õ߿ɴÓÖлñÒæ£¬£¬£¬ÇÒÖÎÁÆÈ±·¦ÓÐÓõÄÔ¤²âÒòËØ¡£¡£¡£Í¬Ê±£¬£¬£¬¸ÃÁÙ´²Ñо¿Ò²Ç¿µ÷ÁËÃâÒßÖÎÁÆÓëÖ×Áö΢ÇéÐε÷Àí¼ÁÏàÁ¬ÏµµÄDZÔÚÖÎÁƼÛÖµ¡£¡£¡£¸Îϸ°û°©¾ßÓÐÖØ´óµÄ²¡ÀíÐÄÀíÆÁÕÏ£¬£¬£¬ÃâÒßϸ°û½þÈó²»Á¼ºÍǿʢµÄÖ×ÁöÃâÒßÒÖÖÆÎ¢ÇéÐÎÊǸÃʵÌåÁöµÄÖ÷ÒªÌØµã¡£¡£¡£²¡ÐÄÀíÑ§ÌØµã¼«´óµØÏÞÖÆÁ˸Îϸ°û°©ÖÐÃâÒßÖÎÁƵÄÓÐÓÃÐÔ¡£¡£¡£Òò´Ë£¬£¬£¬¸ÄÉÆ¸Îϸ°û°©ÃâÒßÒÖÖÆµÄÖ×ÁöÃâÒß΢ÇéÐΣ¬£¬£¬¶ÔÌá¸ßHCC»¼ÕßÃâÒßÖÎÁƵÄÁÆÐ§¾ßÓÐÖ÷ÒªÒâÒå¡£¡£¡£

·ÅÁÆ (Radiotherapy, RT) ÊǸÎϸ°û°©µÄÖ÷Á÷ÖÎÁÆÒªÁìÖ®Ò»¡£¡£¡£RT³ýÖ±½ÓɱÉËÖ×Áöϸ°ûÍ⣬£¬£¬»¹½éµ¼Á˶ÔÖ×Áö΢ÇéÐεÄÃâÒßµ÷Àí×÷Óᣡ£¡£»ùÓÚ·ÅÁƶÔÖ×ÁöÃâÒß΢ÇéÐεÄÓ°Ï죬£¬£¬Ô½À´Ô½¶àµÄÁÙ´²Ç°ºÍÁÙ´²Ñо¿×îÏÈ̽ÌÖ·ÅÁÆÁªºÏÃâÒßÖÎÁƵĿ¹Ö×ÁöÁÆÐ§¡£¡£¡£Ö»¹Ü´ó¶¼Ñо¿ÏÔʾ·ÅÁƺÍÃâÒßÖÎÁÆÁªºÏÖÎÁÆÐ§¹û½ÏºÃ£¬£¬£¬µ«ÈÔ´¦ÓÚ³õ¼¶½×¶Î£¬£¬£¬ÉÐÎÞÖ¸ÄÏÍÆ¼öµÄ·ÅÁÆÁªºÏÃâÒßÖÎÁÆ·½°¸¡£¡£¡£±ðµÄ£¬£¬£¬ÓÐÑо¿·¢Ã÷£¬£¬£¬ÔÚChild-Pugh (CP) ÆÀ·Ö¡Ý7µÄ»¼ÕßÖУ¬£¬£¬Í¨Àý¼ÁÁ¿·ÅÁƺó·ÅÉäÐԸβ¡(RILD)ºÍCPÆÀ·Ö¶ñ»¯µÄ·çÏÕÏÔÖøÔö¸ß¡£¡£¡£Ðí¶à¸Îϸ°û°©»¼ÕßÓиÎÓ²»¯²¡Ê·£¬£¬£¬¸Î¹¦Ð§Ë𺦡¢¡¢Ãž²Âö¸ßѹµÈÊǵ¼ÖÂRILDµÄΣÏÕÒòËØ¡£¡£¡£Òò´Ë£¬£¬£¬½øÒ»²½Ì½ÌÖ·ÅÁÆÓëÃâÒßÖÎÁƵÄЭͬ×÷Ó㬣¬£¬Ì½Ë÷ÁªºÏÖÎÁƺÏÊʵļÁÁ¿ºÍ·½°¸£¬£¬£¬¶Ô¸ÄÉÆHCC»¼ÕßÔ¤ºóÖÁ¹ØÖ÷Òª¡£¡£¡£µÍ¼ÁÁ¿·ÅÉäÖÎÁÆ£¨Low-dose Radiotherapy£¬£¬£¬LDRT) ÔÚÖ×ÁöÃâÒßÖÎÁÆÖеÄÑо¿Ô½À´Ô½¶à¡£¡£¡£ÁÙ´²Ç°Ñо¿Åú×¢£¬£¬£¬LDRT¿Éͨ¹ý˲ʱÑ×Ö¢»¯ÖØËÜÖ×ÁöÃâÒß΢ÇéÐΣ¬£¬£¬Ê¹Æä¸üÊʺÏÓÚ¶àÖÖÖ×ÁöµÄÃâÒßÖÎÁÆ¡£¡£¡£Õâ¸øLDRTÌá¸ßÃâÒßÖÎÁÆÔÚµÍÃâÒßϸ°û½þÈóÖ×ÁöµÄÓÐÓÃÐÔÌṩÁËÀíÂÛ»ù´¡¡£¡£¡£±ðµÄ£¬£¬£¬ÁÙ´²Ö¤¾ÝÅú×¢£¬£¬£¬ÊõǰLDRT¿Éʹ°éÓÐÞ²Âö°©Ë¨µÄ¸Îϸ°û°©»¼Õß½µÆÚ£¬£¬£¬½µµÍÊõºó¸´·¢ÂÊ£¬£¬£¬ÇÒ²»ÔöÌíÊÖÊõ·çÏÕºÍÊõºó¸ÎË¥½ß±¬·¢ÂÊ¡£¡£¡£

±¾Ñо¿ÔÚ¶àÖÖÁÙ´²Ç°¸Î°©Ä£×ÓÖз¢Ã÷µÍ¼ÁÁ¿·ÅÁÆ£¨Low-dose Radiotherapy£¬£¬£¬ LDRT£©¿ÉÒÔÏÔ×ÅÔöÇ¿Ë«ÖØ³ÌÐòÐÔϸ°ûéæÃüÅäÌå-1 (Programmed cell death 1 ligand 1£¬£¬£¬PD-L1) ºÍѪ¹ÜÄÚÆ¤Éú³¤Òò×ÓA (Vascular endothelial growth factor A, VEGFA) ×è¶Ï (Dual PD-L1 and VEGFA Blockade£¬£¬£¬ DPVB) µÄ¿¹Ö×Áö×÷Óᣡ£¡£¸ÃÁªºÏÖÎÁÆÏÔʾ³öÏÔÖøµÄCD8+ Tϸ°û½éµ¼µÄ¿¹Ö×ÁöÖÎÁÆÁÆÐ§¡£¡£¡£¸ßͨÁ¿µ¥Ï¸°ûRNA²âÐòºÍ¶àÖÖʵÑéЧ¹ûÏÔʾ£¬£¬£¬LDRTÁªºÏDPVBÔöÇ¿ÁËÖ×ÁöÇãÔþµÄºÄ½ßÑùCD8+ TexµÄЧӦ¹¦Ð§ºÍϸ°û¶¾ÐÔ¡£¡£¡£±ðµÄ£¬£¬£¬Ê¹Óöà¸ö¸Î°©ÁÙ´²Ç°Ä£×ÓºÍÌåÍâÖ×ÁöƬ¶Ïƽ̨£¨Patient-derived tumor fragments, PDTFs) ¾ÙÐÐÁÆÐ§»úÖÆÉîÈëÑо¿£¬£¬£¬Ð§¹ûÅú×¢LDRTͨ¹ýCXCL10/CXCR3ÖáÔö½ø¸Éϸ°ûÑù׿ºÄ½ßÐÔCD8+ Tpex´ÓÒýÁ÷ÁÜͶºÏÏòÁöÄÚÕÙļ½ø¶øÔöÃôDPVBµÄ»úÖÆ¡£¡£¡£¸ÃÑо¿¹ØÓÚÌá¸ß²»¿ÉÇгý¸Îϸ°û°©µÄÁªºÏÖÎÁÆÁÆÐ§ÌṩÁ˿ɿ¿µÄÁÙ´²Ç°Ö¤¾Ý¡£¡£¡£

27B29CD53DCD7E9F37F6AEA074D_F44184B7_1FF6E

LDRTÁªºÏT+AµÄЭͬ¿¹Ö×Áö×÷ÓÃÁÆÐ§ºÍ»úÖÆ

ngµç×ÓÓÎÏ·Á¥ÊôµÚÈýÒ½Ôº¸ÎÔàÍâ¿ÆÍŶӺã¾Ã¾Û½¹ÓÚ¸ÎÔàÖ×Áö¡¢¡¢Æ÷¹ÙÀäÉúÑļ°¸ÎÒÆÖ²Î§ÊõÆÚ×ÛºÏÖÎÁÆÊֶεĻù´¡Ñо¿ºÍÁÙ´²×ª»¯Ì½Ë÷¡£¡£¡£±¾´ÎÑо¿ÊÇÍŶӵÄÓÖÒ»Ö÷ҪЧ¹û£¬£¬£¬ÎªÌá¸ß²»¿ÉÇгý¸Îϸ°û°©ÌṩÁËеÄÁªºÏÖÎÁÆ·½°¸ºÍÖ¸µ¼T+AÖÎÁÆÌṩÁËDZÔڵıê¼ÇÎï¡£¡£¡£

ÂÛÎÄÁ´½Ó£ºhttps://www.nature.com/articles/s41467-023-43462-1

¡¾ÍøÕ¾µØÍ¼¡¿